

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.¹

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**SIXTEENTH MONTHLY FEE STATEMENT OF FTI CONSULTING, INC. FOR
COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF
EXPENSES INCURRED AS FINANCIAL ADVISOR TO THE AD HOC COMMITTEE
OF GOVERNMENTAL AND OTHER CONTINGENT LITIGATION CLAIMANTS FOR
THE PERIOD FROM JANUARY 1, 2021 THROUGH JANUARY 31, 2021**

Name of Applicant:

FTI Consulting, Inc.

Authorized to provide Professional Services
to:

Ad Hoc Committee of Governmental and
Other Contingent Litigation Claimants

Date of Order Approving Debtors' Payment
of Fees and Expenses of Applicant:

December 2, 2019 [ECF No. 553]

Period for which compensation and
reimbursement is sought:

January 1, 2021 through January 31,
2021

Monthly Fees Incurred:

\$493,773.50

1. The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifesciences Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717), and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Monthly Expenses Incurred: \$0.00

Total Fees and Expenses Due: \$493,773.50

This is a: X monthly ____ interim ____ final application

PRIOR APPLICATIONS:

Docked No./Filed	Compensation Period	Requested		Approved	
		Fees	Expenses	Fees	Expenses
Docket No. 635 Filed On 12/9/2019	9/19/2019 – 10/31/2019	\$778,791.50	\$680.61	\$771,291.50	\$680.61
Docket No. 741 Filed On 1/13/2020	11/1/2019 – 11/30/2019	\$827,575.00	\$899.41	\$820,075.00	\$899.41
Docket No. 852 Filed on 2/20/2020	12/1/2019 – 12/31/2019	\$802,036.50	\$2,284.19	\$794,536.50	\$2,284.19
Docket No. 916 Filed on 3/12/2020	1/1/2020 – 1/31/2020	\$774,662.00	\$11,530.84	\$767,162.00	\$11,530.84
Docket No. 1090 Filed on 4/27/2020	2/1/2020 – 2/29/2020	\$615,089.00	\$6,141.22	\$610,714.00	\$6,141.22
Docket No. 1171 Filed on 5/19/2020	3/1/2020 – 3/31/2020	\$561,863.50	\$67.08	\$557,488.50	\$67.08
Docket No. 1251 Filed on 6/10/2020	4/1/2020 – 4/30/2020	\$428,303.00	\$1,732.28	\$423,928.00	\$1,732.28
Docket No. 1379 Filed on 7/13/2020	5/1/2020 – 5/31/2020	\$303,367.00	\$4,325.26	\$298,992.00	\$4,325.26
Docket No. 1651 Filed on 9/2/2020	6/1/2020 – 6/30/2020	\$374,753.00	\$96.90	\$372,253.00	\$96.90
Docket No. 1725 Filed on 9/25/2020	7/1/2020 – 7/31/2020	\$446,975.50	\$0.00	\$444,475.50	\$0.00
Docket No. 1850 Filed on 10/26/2020	8/1/2020 – 8/31/2020	\$261,092.00	\$108.25	\$258,592.00	\$108.25
Docket No. 1950 Filed on 10/26/2020	9/1/2020 – 9/30/2020	\$357,546.50	\$0.00	\$355,046.50	\$0.00
Docket No. 2031 Filed on 11/24/2020	9/19/2019 – 9/30/2020	\$44,462.00	\$0.00	\$35,569.60	\$0.00
Docket No. 2154 Filed on 12/18/2020	10/1/2020 – 10/31/2020	\$356,078.50	\$0.00	\$284,862.80	\$0.00
Docket No. 2308 Filed on 1/20/2021	11/1/2020 – 11/30/2020	\$450,827.00	\$0.00	\$360,661.60	\$0.00
Docket No. TBU Filed on TBU	12/1/2020 – 12/31/2020	\$308,146.00	\$0.00	-	-

Note: The fee examiner's agreed upon reductions of \$30,000, \$17,500, and \$10,000 were allocated evenly across fees from the first, second, and third interim period, respectively.

This statement (the “**Fee Statement**”) of FTI Consulting, Inc. (together with its wholly owned subsidiaries and independent contractors, “**FTI**”) as financial advisor to the Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants of Purdue Pharma L.P., *et al.* (the “**Committee**”) is submitted in accordance with the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals* [ECF No. 529] and the *Order Authorizing the Debtors to Assume the Reimbursement Agreement and Pay the Fees and Expenses of the Ad Hoc Committee’s Professionals* [ECF No. 553] entered on November 21, 2019 and December 2, 2019, respectively, (the “**Orders**”). In support of this Fee Statement, FTI respectfully states as follows.

1. The fees and expenses for the period from January 1, 2021 through and including January 31, 2021 (the “**Fee Period**”) amount to:

Professional Fees	\$493,773.50
Expenses	<u>0.00</u>
TOTAL	<u>\$493,773.50</u>

2. If no timely and proper objection is made by a party-in-interest within fourteen (14) days after service of this Fee Statement, the Debtors are authorized to pay 80% of professional fees and 100% of out-of-pocket expenses. These amounts are presented below.

Professional Fees at 80%	\$395,018.80
Expenses at 100%	<u>0.00</u>
TOTAL	<u>\$395,018.80</u>

3. The professionals providing services, hourly billing rates, the aggregate hours worked by each professional, and the aggregate hourly fees for each professional during the Fee Period are set forth on the schedule annexed hereto as **Exhibit “A.”**

4. A summary of aggregate hours worked and aggregate hourly fees for each task code during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “B.”**
5. Detailed time entry by task code during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “C.”**
6. FTI reserves the right to request, in subsequent fee statements and applications, reimbursement of any additional expenses incurred during the Fee Period, as such expenses may not have been captured to date in FTI’s billing system.

NOTICE AND OBJECTION PROCEDURES

7. Objections to this Fee Statement, if any, must be filed with the Court and served upon the Notice Parties so as to be received no later than March 31, 2021 (the “**Objection Deadline**”), setting forth the nature of the objection and the amount of fees or expenses at issue (an “**Objection**”).
8. If no objections to this Fee Statement are filed and served as set forth above, the Debtors shall promptly pay eighty percent (80%) of the fees and one hundred percent (100%) of the expenses identified herein.
9. If an objection to this Fee Statement is received on or before the Objection Deadline, the Debtors shall withhold payment of that portion of this Fee Statement to which the objection is directed and promptly pay the remainder of the fees and disbursements in the percentages set forth above. To the extent such an objection is not resolved, it shall be preserved and scheduled for consideration at the next interim fee application hearing to be heard by the Court.

Dated: New York, New York
March 17, 2021

FTI CONSULTING, INC.
Financial Advisors to the Ad Hoc Committee of
Governmental and Other Contingent Litigation
Claimants of Purdue Pharma L.P.

By: /s/ Matthew Diaz
Matthew Diaz, Senior Managing Director
Three Times Square, 10th Floor
New York, New York 10036
Telephone: (212) 499-3611
Email: matt.diaz@fticonsulting.com

EXHIBIT A
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
SUMMARY OF HOURS BY PROFESSIONAL
FOR THE PERIOD JANUARY 1, 2021 TO JANUARY 31, 2021

Professional	Position	Specialty	Billing Rate¹	Total Hours	Total Fees
Diaz, Matthew	Senior Managing Director	Restructuring	\$ 1,120	118.1	132,261.5
Joffe, Steven	Senior Managing Director	Tax	1,165	3.4	3,961.0
Simms, Steven	Senior Managing Director	Restructuring	1,295	6.4	8,288.0
Suric, Emil	Senior Director	Healthcare	850	22.4	19,040.0
Bromberg, Brian	Director	Restructuring	840	198.5	166,740.0
Kim, Ye Darm	Senior Consultant	Restructuring	634	240.5	152,470.0
Kurtz, Emma	Consultant	Restructuring	470	23.0	10,810.0
Hellmund-Mora, Marili	Associate	Restructuring	290	0.7	203.0
GRAND TOTAL			613.0		\$ 493,773.50

1. Reflects blended hourly rates. Billing rates of international professionals have been translated to USD using the relevant spot rate.

EXHIBIT B**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****SUMMARY OF HOURS BY TASK****FOR THE PERIOD JANUARY 1, 2021 TO JANUARY 31, 2021**

Task Code	Task Description	Total Hours	Total Fees
1	Current Operating Results & Events	8.2	\$ 4,569.00
2	Cash & Liquidity Analysis	1.7	1,904.00
6	Asset Sales	76.4	63,162.00
7	Analysis of Domestic Business Plan	176.1	143,803.50
10	Analysis of Tax Issues	7.9	8,385.00
16	Analysis, Negotiate and Form of POR & DS	253.2	203,613.50
18	Review of Historical Transactions	23.4	20,726.00
19	Case Management	6.9	5,217.00
21	General Meetings with Counsel and/or Ad Hoc Committee	14.4	13,141.50
24	Preparation of Fee Application	6.7	4,013.00
28	Review of IAC Business Plan	34.5	23,065.50
29	Intercreditor Allocation	3.6	2,173.50
GRAND TOTAL¹		613.0	\$ 493,773.50

1. Billing rates of international professionals have been translated to USD using the relevant spot rate.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JANUARY 1, 2021 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
1	1/4/2021	Kurtz, Emma	0.6	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/5/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/6/2021	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/7/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/8/2021	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/11/2021	Kurtz, Emma	0.9	Draft summary of current financials and business lines to share with Counsel for Director search.
1	1/11/2021	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/12/2021	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/13/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/14/2021	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/15/2021	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/19/2021	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/20/2021	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/21/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/22/2021	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/25/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/26/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/27/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/28/2021	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/28/2021	Diaz, Matthew	1.1	Review Purdue historical financial statements and operating results.
1	1/29/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1 Total			8.2	
2	1/12/2021	Diaz, Matthew	0.6	Review the domestic business budget to actual results.
2	1/12/2021	Diaz, Matthew	0.5	Review the updated domestic cash flow analysis.
2	1/13/2021	Diaz, Matthew	0.6	Review the updated domestic cash flow analysis.
2 Total			1.7	
6	1/11/2021	Kim, Ye Darm	0.7	Participate in call re: OxyContin sales for bid.
6	1/11/2021	Kim, Ye Darm	0.9	Review updated bid proposal.
6	1/12/2021	Bromberg, Brian	1.0	Discuss updated bid proposal with Houlihan.
6	1/12/2021	Bromberg, Brian	0.8	Discuss updated bid proposal with team.
6	1/12/2021	Kim, Ye Darm	0.8	Participate in discussion re: bid diligence analysis.
6	1/12/2021	Kurtz, Emma	0.2	Participate in internal call to discuss bid proposal and how to value the bid.
6	1/12/2021	Kim, Ye Darm	0.8	Participate on call re: revised bid proposal discussion.
6	1/12/2021	Diaz, Matthew	0.7	Perform detailed review of the updated bid received.
6	1/12/2021	Kim, Ye Darm	0.8	Review HL draft bid diligence presentation.
6	1/12/2021	Kurtz, Emma	0.4	Review proposed bid to understand terms and payout structure.
6	1/12/2021	Bromberg, Brian	3.5	Review terms of the updated bid proposal.
6	1/13/2021	Bromberg, Brian	0.8	Continue review of updated buyer bid model.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JANUARY 1, 2021 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
6	1/13/2021	Bromberg, Brian	0.3	Discuss buyer bid with Houlihan team.
6	1/13/2021	Kurtz, Emma	0.7	Discuss internally re: bid and modeling of proposed payout to various creditor groups.
6	1/13/2021	Bromberg, Brian	0.9	Discuss updated buyer bid financial inputs with team.
6	1/13/2021	Bromberg, Brian	0.7	Discuss updated buyer bid with counsel.
6	1/13/2021	Bromberg, Brian	1.0	Discuss updated buyer bid with Debtor team.
6	1/13/2021	Bromberg, Brian	1.0	Discuss updated buyer bid with Houlihan team.
6	1/13/2021	Diaz, Matthew	0.5	Participate in a call with counsel to discuss the proposed bid.
6	1/13/2021	Diaz, Matthew	1.1	Participate in a call with HL to discuss the bid presentation and related next steps.
6	1/13/2021	Diaz, Matthew	0.8	Participate in a call with the Debtors to discuss the proposed bid.
6	1/13/2021	Kim, Ye Darm	0.8	Participate in call to discuss bid diligence.
6	1/13/2021	Kim, Ye Darm	1.1	Participate in call with Debtors re: bid diligence.
6	1/13/2021	Kim, Ye Darm	1.5	Participate in call with HL to discuss bid diligence.
6	1/13/2021	Bromberg, Brian	1.0	Participate in Committee call re: updated bid.
6	1/13/2021	Diaz, Matthew	1.6	Review the sensitivity and royalty analysis on the proposed bid.
6	1/13/2021	Bromberg, Brian	1.8	Review updated buyer bid financial model.
6	1/14/2021	Bromberg, Brian	0.8	Review proposed economics of the updated bid.
6	1/14/2021	Kim, Ye Darm	2.7	Review supporting schedules for bid proposal.
6	1/15/2021	Bromberg, Brian	0.9	Discuss updated bid proposal with Houlihan.
6	1/15/2021	Diaz, Matthew	1.2	Participate in a call with HL to discuss the cash flows and related implications of the bid.
6	1/15/2021	Kim, Ye Darm	1.0	Participate in call re: revised bid supporting schedules.
6	1/15/2021	Kim, Ye Darm	1.2	Process revisions to revised bid forecast comparison analysis.
6	1/15/2021	Diaz, Matthew	1.6	Review of the bid financing package.
6	1/15/2021	Bromberg, Brian	3.7	Review updated bid financial model.
6	1/16/2021	Bromberg, Brian	2.2	Finalize and share bridge of bid forecasts to business plan.
6	1/16/2021	Diaz, Matthew	0.3	Participate in a call with HL to discuss the bid received.
6	1/16/2021	Diaz, Matthew	0.6	Participate in a call with Province on the bid received.
6	1/16/2021	Diaz, Matthew	1.0	Participate in a call with the Debtors on the bid received.
6	1/16/2021	Bromberg, Brian	1.0	Participate in call with Debtors re: bid proposal.
6	1/16/2021	Kim, Ye Darm	0.9	Participate in call with Debtors re: revised bid diligence.
6	1/16/2021	Bromberg, Brian	1.0	Participate in call with UCC re: updated bid proposal.
6	1/16/2021	Kim, Ye Darm	0.3	Participate in pre-call with financial advisors re: revised bid diligence.
6	1/16/2021	Bromberg, Brian	1.0	Review diligence questions for bidder.
6	1/16/2021	Kim, Ye Darm	0.9	Review revised bid diligence questions list.
6	1/16/2021	Diaz, Matthew	1.5	Review the bid received and the related cash flows and due diligence list.
6	1/19/2021	Simms, Steven	0.3	Review updates on proposed bid diligence items.
6	1/20/2021	Bromberg, Brian	1.0	Coordinate buyer diligence with UCC and Debtor advisors.
6	1/20/2021	Diaz, Matthew	1.0	Participate in a call with bidder to discuss open questions on his bid.
6	1/20/2021	Kim, Ye Darm	1.1	Participate in call with Debtors re: bid proposal diligence workplan.
6	1/20/2021	Bromberg, Brian	1.2	Participate in call with potential buyer.
6	1/20/2021	Bromberg, Brian	0.8	Participate in debrief call after call with potential buyer.
6	1/20/2021	Kim, Ye Darm	0.7	Participate in follow-up call re: bid proposal next steps.
6	1/20/2021	Kim, Ye Darm	0.7	Review bid financing letters.
6	1/20/2021	Kim, Ye Darm	0.6	Review bid proposal diligence responses to question list.
6	1/20/2021	Bromberg, Brian	1.5	Review buyer materials to prepare for call with buyer.
6	1/21/2021	Kim, Ye Darm	1.8	Create live version of bid model to allow for sensitivities.
6	1/21/2021	Bromberg, Brian	0.6	Discuss bidder licensing modeling with Debtors.
6	1/21/2021	Kim, Ye Darm	0.8	Participate on call w/ HL and PJT re: dynamic bid model analysis.
6	1/21/2021	Kim, Ye Darm	1.2	Review HL dynamic bid model
6	1/22/2021	Kim, Ye Darm	1.1	Participate in call with AHC re: bid scenario.
6	1/22/2021	Kim, Ye Darm	1.2	Prepare comparative analysis re: bid and core business distributable value scenarios.
6	1/22/2021	Suric, Emil	1.0	Review bid proposal economics analysis and prepare for discussion.
6	1/25/2021	Simms, Steven	0.4	Participate in correspondence re: proposed bid.
6	1/26/2021	Bromberg, Brian	1.7	Review new bid proposal materials.
6	1/26/2021	Bromberg, Brian	1.5	Review product forecast information re: bidder.
6	1/26/2021	Diaz, Matthew	0.8	Review the updated bid proposal analysis.
6	1/27/2021	Bromberg, Brian	1.3	Discuss potential buyer proposal with Houlihan and counsel.
6	1/27/2021	Diaz, Matthew	0.6	Participate (partially) in a call with Counsel to consider certain aspects of the bid.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JANUARY 1, 2021 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
6	1/27/2021	Kim, Ye Darm	1.5	Participate in call re: bid proposal next steps.
6	1/27/2021	Diaz, Matthew	0.7	Review of the questions on the proposed bid.
6	1/31/2021	Diaz, Matthew	1.3	Review of the Province analysis on the proposed bid.
6 Total			76.4	
7	1/1/2021	Bromberg, Brian	3.3	Iterate versions of scenario slides with Houlihan team.
7	1/4/2021	Bromberg, Brian	0.7	Discuss scenarios presentation with Houlihan team.
7	1/4/2021	Bromberg, Brian	0.8	Discuss status of domestic business plan diligence workstreams with internal team.
7	1/4/2021	Suric, Emil	0.8	Participate in Internal discussion with team to discuss updated/refreshed forecasts and sensitivities on OxyContin for revised business plan.
7	1/4/2021	Kim, Ye Darm	0.5	Participate on call re: OxyContin forecast assumptions.
7	1/4/2021	Bromberg, Brian	3.3	Perform research re: managed care assumptions.
7	1/4/2021	Bromberg, Brian	0.9	Prepare for call on domestic diligence workstream status.
7	1/4/2021	Bromberg, Brian	1.5	Research and respond to questions from Debtors re: business plan diligence.
7	1/4/2021	Bromberg, Brian	0.6	Review core scenarios with Debtor advisors.
7	1/4/2021	Suric, Emil	2.1	Review information provided by management and the latest analysis of business plan.
7	1/4/2021	Bromberg, Brian	2.3	Review latest OxyContin forecasting assumptions.
7	1/4/2021	Bromberg, Brian	2.2	Review scenarios presentation in response to UCC questions.
7	1/4/2021	Kim, Ye Darm	0.4	Review slides re: downside case from Debtors.
7	1/4/2021	Diaz, Matthew	1.1	Review the latest domestic December business plan.
7	1/4/2021	Diaz, Matthew	0.8	Review the updated OxyContin downside case.
7	1/4/2021	Bromberg, Brian	2.8	Summarize notes on managed care assumptions.
7	1/5/2021	Suric, Emil	2.9	Continue refresh of OxyContin sensitivities and independent forecasts for base case.
7	1/5/2021	Diaz, Matthew	1.1	Detail review of the OxyContin forecast and related sensitivities.
7	1/5/2021	Bromberg, Brian	0.9	Discuss OxyContin forecast with internal team.
7	1/5/2021	Bromberg, Brian	1.1	Discuss OxyContin forecast with valuation team.
7	1/5/2021	Bromberg, Brian	0.8	Finalize draft domestic scenarios presentation.
7	1/5/2021	Kurtz, Emma	1.1	Participate in call to discuss OxyContin downside forecast.
7	1/5/2021	Bromberg, Brian	0.8	Participate in call with UCC advisors.
7	1/5/2021	Bromberg, Brian	0.5	Participate in pre call with Houlihan team re: scenarios presentation.
7	1/5/2021	Bromberg, Brian	2.3	Prepare for call with UCC advisors on scenarios.
7	1/5/2021	Suric, Emil	1.0	Prepare updated base and low case scenarios along with a presentation of a bridge to the prior sensitivity analysis.
7	1/5/2021	Suric, Emil	1.2	Refresh OxyContin sensitivities and independent forecasts for illustrative downside case.
7	1/5/2021	Bromberg, Brian	3.2	Review downside cases for business plan diligence.
7	1/6/2021	Kim, Ye Darm	1.1	Participate in AHC meeting re: mediation.
7	1/6/2021	Bromberg, Brian	0.8	Review contingencies backup and assumptions for scenarios presentation.
7	1/6/2021	Kim, Ye Darm	0.4	Review support documents for contingency estimates.
7	1/7/2021	Bromberg, Brian	1.0	Discuss contingencies assumptions with internal team.
7	1/7/2021	Bromberg, Brian	1.3	Discuss OxyContin forecast assumptions with team.
7	1/8/2021	Bromberg, Brian	1.3	Participate in OxyContin forecast call with Debtors.
7	1/8/2021	Bromberg, Brian	0.7	Prepare for call on OxyContin forecast diligence.
7	1/8/2021	Bromberg, Brian	1.6	Prepare summary of OxyContin forecast diligence call for internal use.
7	1/8/2021	Bromberg, Brian	0.5	Review domestic business scenario sensitivities.
7	1/8/2021	Diaz, Matthew	0.4	Review notes and related next steps coming out of OxyContin forecast diligence call.
7	1/9/2021	Bromberg, Brian	0.5	Confirm PEO sharing issues with Debtors re: domestic business plan.
7	1/11/2021	Bromberg, Brian	0.7	Continue review of Rhodes segment level financial information.
7	1/11/2021	Suric, Emil	1.5	Prepare downside case sensitivity analysis and review of call notes.
7	1/11/2021	Bromberg, Brian	1.1	Prepare OxyContin call agenda.
7	1/11/2021	Suric, Emil	1.1	Review business plan and prepare agenda for discussion with management.
7	1/11/2021	Diaz, Matthew	0.8	Review of OxyContin forecast due diligence and related question list for the call with the Debtors.
7	1/11/2021	Bromberg, Brian	1.2	Review OxyContin forecast diligence items with internal team.
7	1/11/2021	Bromberg, Brian	1.0	Review Rhodes segment level financial information.
7	1/12/2021	Diaz, Matthew	1.1	Participate in a call with Purdue to discuss the OxyContin forecast.
7	1/12/2021	Kim, Ye Darm	0.7	Participate in call re: OxyContin forecast assumptions analysis.
7	1/12/2021	Bromberg, Brian	1.1	Participate in call with Debtors on OxyContin and Adhansia.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JANUARY 1, 2021 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
7	1/12/2021	Kim, Ye Darm	1.1	Participate in call with Debtors to discuss OxyContin / Adhansia forecast assumptions with the commercial team.
7	1/12/2021	Suric, Emil	1.2	Participate in due diligence call with Purdue management.
7	1/12/2021	Suric, Emil	0.5	Participate in regroup to discuss commentary provided by Management on due diligence call.
7	1/12/2021	Suric, Emil	0.4	Prepare for call with Purdue Management to discuss updated business plan assumptions.
7	1/12/2021	Suric, Emil	0.8	Process updates to base case and downside case based on Management commentary provided in due diligence call.
7	1/12/2021	Bromberg, Brian	1.7	Review analysis of license payments.
7	1/12/2021	Diaz, Matthew	1.1	Review the updated OxyContin forecast sensitivity.
7	1/13/2021	Kim, Ye Darm	0.5	Recalculate pipeline operating profit assumptions in new business plan.
7	1/13/2021	Kim, Ye Darm	0.9	Review pipeline operating profit assumptions.
7	1/13/2021	Bromberg, Brian	1.0	Review royalty model.
7	1/13/2021	Suric, Emil	0.5	Update base case and downside case scenario for updated prescription data provided on OxyContin.
7	1/14/2021	Suric, Emil	0.5	Conduct further sensitivity on base case scenario regression.
7	1/14/2021	Suric, Emil	2.0	Model an upside case scenario based on longer assumed patent life.
7	1/14/2021	Suric, Emil	0.6	Review new data provided by Management detailing forecasts.
7	1/14/2021	Bromberg, Brian	0.5	Review newly uploaded OxyContin information.
7	1/14/2021	Kim, Ye Darm	2.4	Review updated forecast supporting schedules provided in the dataroom.
7	1/14/2021	Kim, Ye Darm	0.7	Review updated FTI OxyContin forecast analysis.
7	1/14/2021	Suric, Emil	2.5	Update base case and downside case scenarios based on detailed forecasts provided by Management.
7	1/15/2021	Kim, Ye Darm	1.3	Compare forecasts in revised bid schedules with Debtors' assumptions.
7	1/15/2021	Kim, Ye Darm	3.2	Compare operating expense and sales assumptions in revised bid forecasts relative to Debtors' assumptions.
7	1/15/2021	Kim, Ye Darm	1.8	Compare product forecasts in revised bid schedules to the latest business plan.
7	1/15/2021	Bromberg, Brian	2.3	Edit bridge from bid proposal forecasts to business plan.
7	1/15/2021	Kim, Ye Darm	0.4	Review pipeline cash flow assumptions from Debtors.
7	1/15/2021	Diaz, Matthew	1.2	Review the December business plan model.
7	1/18/2021	Bromberg, Brian	1.2	Review latest Debtor business plan forecasts.
7	1/19/2021	Bromberg, Brian	1.0	Continue to finalize draft of domestic business scenarios presentation to send to UCC.
7	1/19/2021	Bromberg, Brian	0.9	Discuss domestic business scenarios with Houlihan.
7	1/19/2021	Bromberg, Brian	1.0	Finalize draft of domestic business scenarios presentation to send to UCC.
7	1/19/2021	Bromberg, Brian	2.7	Provide comments on domestic business scenario slides.
7	1/19/2021	Bromberg, Brian	1.7	Review bridge files for domestic business scenarios.
7	1/20/2021	Bromberg, Brian	1.0	Discuss domestic business plan diligence with Houlihan.
7	1/20/2021	Bromberg, Brian	0.7	Discuss restricted cash with Houlihan and Debtors.
7	1/20/2021	Kim, Ye Darm	1.8	Prepare bridge analysis to Debtor core case.
7	1/20/2021	Kim, Ye Darm	1.2	Review PJT presentation re: segment level cash flows and compare to December business plan.
7	1/20/2021	Diaz, Matthew	1.4	Review the proposed opex budgeted amounts and projected savings.
7	1/20/2021	Bromberg, Brian	1.4	Review updates to the domestic business scenarios presentation.
7	1/20/2021	Kim, Ye Darm	0.7	Review YTD cost files provided by the Debtors.
7	1/21/2021	Bromberg, Brian	2.2	Create updated core case scenario cash flow.
7	1/21/2021	Bromberg, Brian	1.7	Discuss and edit plan B scenario presentation.
7	1/21/2021	Kurtz, Emma	0.3	Discuss internally re: latest business plan projections and operating expenses benchmarking to comparable companies.
7	1/21/2021	Bromberg, Brian	0.7	Discuss operating expense benchmarking with team.
7	1/21/2021	Bromberg, Brian	0.7	Discuss scenarios presentation with UCC advisors.
7	1/21/2021	Kim, Ye Darm	0.4	Participate on call re: OpEx analysis.
7	1/21/2021	Kim, Ye Darm	0.2	Participate on call re: OpEx analysis.
7	1/21/2021	Kim, Ye Darm	1.6	Prepare comparative OpEx analysis.
7	1/21/2021	Bromberg, Brian	2.8	Review bidder licensing scenario model.
7	1/21/2021	Kim, Ye Darm	0.5	Review OpEx analysis comp set.
7	1/21/2021	Bromberg, Brian	1.2	Review scenarios presentation in response to UCC edits.
7	1/22/2021	Bromberg, Brian	1.0	Create update core case scenario cash flow.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JANUARY 1, 2021 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
7	1/22/2021	Bromberg, Brian	1.0	Discuss Plan B scenarios with counsel.
7	1/22/2021	Bromberg, Brian	1.1	Discuss update to scenarios presentation with Houlihan.
7	1/22/2021	Bromberg, Brian	1.6	Participate in call with Committee on domestic business scenarios analysis.
7	1/22/2021	Bromberg, Brian	0.8	Participate in call with UCC re: domestic business scenarios joint presentation.
7	1/22/2021	Bromberg, Brian	1.3	Prepare forecasts re: liquidity scenarios.
7	1/22/2021	Kim, Ye Darm	1.6	Process revision to OpEx comp analysis.
7	1/22/2021	Kim, Ye Darm	0.3	Process revisions to the OxyContin upside/downside impact slides.
7	1/22/2021	Kim, Ye Darm	1.1	Process revisions to upside and downside business plan considerations.
7	1/22/2021	Bromberg, Brian	2.1	Review domestic business plan model to compare with scenarios.
7	1/22/2021	Bromberg, Brian	1.2	Review updated slides for scenarios presentation.
7	1/22/2021	Kim, Ye Darm	0.3	Update the OxyContin upside/downside impact slide.
7	1/23/2021	Bromberg, Brian	1.2	Create new slides for scenarios presentation.
7	1/23/2021	Bromberg, Brian	1.8	Discuss updated scenarios model and presentation with team.
7	1/23/2021	Bromberg, Brian	2.3	Review Plan B presentation and provide comments.
7	1/23/2021	Bromberg, Brian	3.7	Review scenarios model and provide comments to Houlihan.
7	1/23/2021	Kim, Ye Darm	0.4	Update slide re: open items on Debtors' forecasts.
7	1/24/2021	Bromberg, Brian	2.5	Comment on and process revisions new slides re: domestic business scenarios.
7	1/24/2021	Bromberg, Brian	1.3	Prepare bridge of prior and updated cash balance assumptions.
7	1/24/2021	Bromberg, Brian	2.7	Review and process revisions to new waterfall slides.
7	1/24/2021	Bromberg, Brian	3.0	Review new version of scenarios model and provide comments.
7	1/25/2021	Bromberg, Brian	0.7	Discuss domestic scenarios presentation with UCC.
7	1/25/2021	Bromberg, Brian	1.1	Participate in call on domestic scenarios with UCC.
7	1/25/2021	Bromberg, Brian	0.7	Participate in pre call on domestic business scenarios.
7	1/25/2021	Kim, Ye Darm	1.2	Prepare analysis re: OpCo cash flows bridge with Debtors' figures.
7	1/25/2021	Bromberg, Brian	1.3	Review domestic business historical working capital movements.
7	1/25/2021	Diaz, Matthew	1.2	Review the OpCo analysis and projected savings assumptions.
7	1/26/2021	Suric, Emil	0.8	Conduct market research on inhalers.
7	1/26/2021	Bromberg, Brian	1.3	Finalize and send Excel to Debtor advisors re: new scenario.
7	1/26/2021	Kim, Ye Darm	1.4	Link bridge analysis to Debtors' source files.
7	1/26/2021	Kim, Ye Darm	0.4	Participate in call re: clean bridge to Debtor figures.
7	1/26/2021	Kim, Ye Darm	0.9	Prepare presentation slide re: opex comparison analysis.
7	1/26/2021	Bromberg, Brian	0.8	Review historical working capital movements.
7	1/26/2021	Bromberg, Brian	1.5	Review Houlihan cash flow model.
7	1/26/2021	Kim, Ye Darm	0.6	Update bridge analysis for updated opex comparison analysis.
7	1/26/2021	Kim, Ye Darm	1.3	Update bridge analysis to Debtor's core only figures.
7	1/26/2021	Bromberg, Brian	0.8	Work on comparable operating expense slide.
7	1/27/2021	Bromberg, Brian	1.8	Continue to bridge segment cash flow numbers from prior analysis.
7	1/27/2021	Bromberg, Brian	0.8	Discuss new domestic business scenario with Debtor advisors.
7	1/27/2021	Kim, Ye Darm	0.4	Process updates to OpEx comparison slide for updated figures.
7	1/27/2021	Bromberg, Brian	3.5	Review bridge analysis re: cash flow numbers from prior analysis.
7	1/27/2021	Kim, Ye Darm	0.8	Review Debtors' prior opioid only case for assumptions re: bridging analysis.
7	1/28/2021	Bromberg, Brian	0.6	Discuss Purdue liquidity with internal healthcare team.
7	1/29/2021	Bromberg, Brian	0.9	Review updated Houlihan model on cash flow scenarios.
7 Total			176.1	
10	1/4/2021	Bromberg, Brian	0.7	Review updated IAC tax questions.
10	1/6/2021	Joffe, Steven	0.5	Participate in AHC professionals call re: tax issues.
10	1/11/2021	Bromberg, Brian	1.0	Participate in a call with KPMG and the other key case stakeholders.
10	1/11/2021	Diaz, Matthew	1.0	Participate in a call with KPMG and the other key case stakeholders.
10	1/11/2021	Diaz, Matthew	0.4	Participate in a call with the AHC professionals to discuss IAC tax due diligence.
10	1/11/2021	Diaz, Matthew	0.3	Participate in a tax call with Province to discuss IAC tax implications.
10	1/11/2021	Diaz, Matthew	0.6	Preparation for the IAC tax call with KPMG and other key case stakeholders.
10	1/11/2021	Bromberg, Brian	0.5	Prepare for call with KPMG and the other key case stakeholders.
10	1/13/2021	Joffe, Steven	0.5	Participate in AHC call re: tax issues.
10	1/19/2021	Joffe, Steven	0.3	Participate in AHC call re: IAC tax issues.
10	1/22/2021	Joffe, Steven	1.1	Participate in AHC professionals call re: tax issues.
10	1/27/2021	Joffe, Steven	1.0	Participate in AHC professionals call re: tax issues.
10 Total			7.9	
16	1/4/2021	Kim, Ye Darm	0.8	Participate in call with PJT re: distributable value scenario assumptions.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JANUARY 1, 2021 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
16	1/4/2021	Diaz, Matthew	2.3	Review the updated distributable value presentation.
16	1/5/2021	Diaz, Matthew	0.5	Participate in a call with Houlihan to prepare for the call with Province re: distributable value.
16	1/5/2021	Diaz, Matthew	0.7	Participate in a call with Province to discuss the distributable value analysis.
16	1/5/2021	Kim, Ye Darm	0.8	Participate in call w/ UCC re: OxyContin forecast sensitivities.
16	1/5/2021	Simms, Steven	0.6	Participate in correspondence with AHC on term sheet and mediation.
16	1/5/2021	Kim, Ye Darm	0.7	Participate in discussion re: revised OxyContin sensitivity assumptions.
16	1/5/2021	Kim, Ye Darm	0.5	Participate in pre-call with HL re: OxyContin forecast disc. with UCC.
16	1/5/2021	Diaz, Matthew	1.8	Perform final review of the Purdue distributable value presentation and provide comments to Houlihan.
16	1/5/2021	Kim, Ye Darm	0.9	Process revisions to distributable value strategic options presentation.
16	1/5/2021	Kim, Ye Darm	1.1	Review refresh of OxyContin sensitivities.
16	1/5/2021	Kim, Ye Darm	0.6	Review summary on potential downside situation re: managed care.
16	1/5/2021	Diaz, Matthew	1.1	Review the updated term sheet.
16	1/5/2021	Kim, Ye Darm	0.9	Review updated OxyContin forecasts for revised downside haircut.
16	1/6/2021	Bromberg, Brian	1.0	Participate in call re: governance for domestic business.
16	1/6/2021	Kim, Ye Darm	0.9	Review latest HL model re: distributable value scenarios.
16	1/6/2021	Diaz, Matthew	1.5	Review the updated recovery analysis presentation.
16	1/7/2021	Kim, Ye Darm	0.7	Participate in call w/ PJT re: settlement assumptions.
16	1/7/2021	Bromberg, Brian	0.7	Participate in call with Debtor advisors on settlements.
16	1/7/2021	Diaz, Matthew	0.7	Review of the distributable value analysis open due diligence and related next steps.
16	1/7/2021	Diaz, Matthew	0.6	Review the updated term sheet with the NCSG.
16	1/8/2021	Kim, Ye Darm	1.4	Participate in call w/ Debtors re: OxyContin sensitivity assumptions.
16	1/8/2021	Kim, Ye Darm	1.2	Prepare slides re: distributable value sensitivity scenarios.
16	1/8/2021	Kim, Ye Darm	0.4	Process revisions to slides re: distributable value sensitivity scenarios.
16	1/8/2021	Diaz, Matthew	1.2	Review the Province net distributable value analysis.
16	1/8/2021	Diaz, Matthew	0.6	Review the updated sensitivities on the distributable value analysis.
16	1/8/2021	Kim, Ye Darm	1.0	Review UCC presentation re: distributable value scenarios.
16	1/8/2021	Kim, Ye Darm	0.9	Update distributable value model for sensitivity toggles.
16	1/12/2021	Diaz, Matthew	0.4	Participate in a call with counsel to discuss plan b alternatives.
16	1/12/2021	Kim, Ye Darm	2.6	Prepare illustrative payout analysis re: bid diligence.
16	1/12/2021	Kim, Ye Darm	0.6	Prepare slide re: sensitivity assumptions to distributable value.
16	1/12/2021	Kim, Ye Darm	2.3	Process additional revisions to illustrative payout analysis re: bid diligence.
16	1/12/2021	Kim, Ye Darm	1.9	Process revisions to illustrative payout analysis re: bid diligence.
16	1/12/2021	Kim, Ye Darm	2.1	Process updates to the illustrative payout analysis re: bid diligence.
16	1/12/2021	Diaz, Matthew	0.9	Review the updated distributable value analysis based on the bid received.
16	1/13/2021	Diaz, Matthew	0.6	Participate in a call with Province to discuss certain strategic alternatives.
16	1/13/2021	Kim, Ye Darm	1.1	Participate in call re: illustrative payout analysis.
16	1/13/2021	Kim, Ye Darm	2.8	Process additional revisions to the illustrative payout analysis.
16	1/13/2021	Kim, Ye Darm	2.9	Process revisions to the illustrative payout analysis.
16	1/13/2021	Diaz, Matthew	0.6	Review the strategic alternatives presentation to the Committee.
16	1/14/2021	Diaz, Matthew	0.4	Draft correspondence to Counsel re: certain strategic alternatives.
16	1/14/2021	Diaz, Matthew	0.4	Research and draft correspondence to Counsel in connection with certain distributable value assumptions.
16	1/14/2021	Diaz, Matthew	1.1	Review the updated distributable value analysis.
16	1/14/2021	Diaz, Matthew	0.6	Review the updated plan term sheet.
16	1/15/2021	Bromberg, Brian	0.5	Discuss plan B scenarios with team.
16	1/15/2021	Kim, Ye Darm	1.0	Participate in call re: mediation w/ NCSG.
16	1/15/2021	Bromberg, Brian	1.0	Participate in mediation call re: future of Purdue.
16	1/15/2021	Diaz, Matthew	0.9	Participate in the mediator meeting with the AHC and the NCSG.
16	1/15/2021	Kim, Ye Darm	0.6	Review latest HL distributable value analysis.
16	1/15/2021	Diaz, Matthew	0.6	Review the distributable value analysis and Province's comments to it.
16	1/16/2021	Kim, Ye Darm	3.4	Build updated distributable value model for updated scenarios.
16	1/16/2021	Kim, Ye Darm	1.2	Revise distributable value model for new assumptions.
16	1/17/2021	Kim, Ye Darm	3.3	Prepare draft presentation on distributable value scenarios and sensitivities.
16	1/17/2021	Kim, Ye Darm	1.5	Process revisions to the distributable value presentation.
16	1/17/2021	Kim, Ye Darm	2.6	Process revisions to the updated distributable model for new sensitivities.
16	1/17/2021	Kim, Ye Darm	0.9	Process revisions to the updated distributable model.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JANUARY 1, 2021 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
16	1/17/2021	Bromberg, Brian	3.2	Review and edit plan b scenarios slides.
16	1/18/2021	Kim, Ye Darm	2.3	Continue processing revisions to the distributable value scenarios model.
16	1/18/2021	Bromberg, Brian	1.0	Discuss plan B scenarios with team.
16	1/18/2021	Kim, Ye Darm	0.5	Participate in call re: distributable value scenarios presentation.
16	1/18/2021	Kim, Ye Darm	0.5	Participate in call w/ HL re: distributable value assumptions.
16	1/18/2021	Kim, Ye Darm	3.1	Process revisions to the distributable model scenarios presentation.
16	1/18/2021	Kim, Ye Darm	3.5	Process revisions to the distributable value scenarios model.
16	1/18/2021	Bromberg, Brian	1.2	Review and edit plan b scenarios slides.
16	1/18/2021	Diaz, Matthew	0.7	Review the updated pages to the plan term sheet.
16	1/18/2021	Diaz, Matthew	2.5	Review the updated plan b case.
16	1/19/2021	Kim, Ye Darm	0.6	Build settlement check calculation into model.
16	1/19/2021	Kim, Ye Darm	1.1	Continue processing revisions to presentation on distributable value allocation.
16	1/19/2021	Simms, Steven	0.4	Correspond with team for updates on mediation issues.
16	1/19/2021	Bromberg, Brian	1.0	Discuss plan B scenarios with team.
16	1/19/2021	Kim, Ye Darm	0.7	Participate in call with HL re: distributable value sensitivities.
16	1/19/2021	Kim, Ye Darm	0.6	Participate in discussion re: distributable value sensitivity assumptions.
16	1/19/2021	Diaz, Matthew	3.3	Perform detailed review and provide updates to the plan b report.
16	1/19/2021	Kim, Ye Darm	1.8	Prepare presentation slides re: sensitivity to distributable value scenarios.
16	1/19/2021	Kim, Ye Darm	1.4	Process revision to slides re: distributable value scenarios.
16	1/19/2021	Kim, Ye Darm	0.9	Process revisions to presentation re: distributable value sensitivity scenarios.
16	1/19/2021	Bromberg, Brian	2.8	Review and edit plan b scenarios slides.
16	1/19/2021	Kim, Ye Darm	1.6	Update analysis re: adjusted Debtor cases for distributable value.
16	1/19/2021	Kim, Ye Darm	3.2	Update model re: allocation scenarios for low sensitivities.
16	1/19/2021	Kim, Ye Darm	1.0	Update model to toggle sensitivity assumptions.
16	1/20/2021	Kim, Ye Darm	1.2	Continue preparing analysis re: cash flow bridges to distributable value scenarios.
16	1/20/2021	Kim, Ye Darm	0.4	Correspond with HL re: cash flow adjustment assumptions in distributable value calculations.
16	1/20/2021	Diaz, Matthew	1.1	Participate in a call with third party and the other case professionals to discuss due diligence questions.
16	1/20/2021	Diaz, Matthew	1.2	Participate in a call with Houlihan, Province and the Debtors' advisors to discuss the side by side analysis.
16	1/20/2021	Kim, Ye Darm	1.1	Process revisions to allocation slides re: distributable value allocation.
16	1/20/2021	Diaz, Matthew	1.6	Review the updated plan b analysis.
16	1/20/2021	Kim, Ye Darm	1.3	Update model for latest distributable value allocation assumptions.
16	1/21/2021	Bromberg, Brian	0.8	Discuss term sheet documents and outstanding questions with team.
16	1/21/2021	Diaz, Matthew	1.1	Participate in a call with counsel to discuss the plan and certain distribution mechanisms.
16	1/21/2021	Diaz, Matthew	0.6	Participate in a call with Houlihan to discuss the recovery analysis.
16	1/21/2021	Diaz, Matthew	0.6	Participate in a call with Province to discuss the plan b analysis.
16	1/21/2021	Kim, Ye Darm	0.5	Participate in call re: additional plan b scenario.
16	1/21/2021	Kim, Ye Darm	0.3	Participate in call re: min cash distributions analysis.
16	1/21/2021	Kim, Ye Darm	0.2	Participate on call re: UCC comments to plan b deck.
16	1/21/2021	Kim, Ye Darm	1.3	Prepare sensitivity analysis of plan b scenario.
16	1/21/2021	Kim, Ye Darm	0.4	Process revisions to plan b scenarios presentation.
16	1/21/2021	Kim, Ye Darm	1.3	Process updates to additional plan b scenario analysis.
16	1/21/2021	Diaz, Matthew	0.8	Review comments from Province re: the plan b report.
16	1/21/2021	Diaz, Matthew	0.7	Review of the updated recovery analysis.
16	1/21/2021	Diaz, Matthew	0.6	Review the updated plan b presentation.
16	1/21/2021	Kim, Ye Darm	0.3	Review UCC comments re: plan b presentation.
16	1/21/2021	Kim, Ye Darm	1.1	Review updated term sheet excerpt.
16	1/22/2021	Diaz, Matthew	1.1	Call with Houlihan and Province on the plan b analysis.
16	1/22/2021	Diaz, Matthew	1.1	Call with the mediation sub group to discuss the plan b analysis.
16	1/22/2021	Kim, Ye Darm	0.7	Continue review of latest HL distributable model assumptions.
16	1/22/2021	Diaz, Matthew	3.4	Perform detailed review of the updated side by side presentation
16	1/22/2021	Kim, Ye Darm	0.4	Process revisions to comparative distributable slide.
16	1/22/2021	Kim, Ye Darm	0.7	Process revisions to comparative distributable value analysis.
16	1/22/2021	Diaz, Matthew	1.3	Review of the updated plan b analysis.
16	1/22/2021	Diaz, Matthew	0.6	Review the updated distributable value downside case.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JANUARY 1, 2021 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
16	1/22/2021	Kim, Ye Darm	1.2	Review updated HL distributable value model.
16	1/23/2021	Kim, Ye Darm	1.0	Participate in call re: distributable value presentation assumptions.
16	1/23/2021	Kim, Ye Darm	0.3	Participate in call re: strategic options presentation.
16	1/23/2021	Diaz, Matthew	3.1	Perform detailed review and edit the side by side presentation.
16	1/23/2021	Kim, Ye Darm	1.7	Review contingency and cash flow assumptions in distributable value model.
16	1/23/2021	Kim, Ye Darm	1.2	Review draft of economic analysis of strategic options presentation.
16	1/23/2021	Kim, Ye Darm	1.1	Review updated HL Distributable Value model.
16	1/24/2021	Kim, Ye Darm	1.4	Build bridge analysis to PJT figures.
16	1/24/2021	Kim, Ye Darm	1.0	Create analysis re: min cash surplus / deficit.
16	1/24/2021	Diaz, Matthew	1.6	Perform detailed review of the allocation analysis slides of the distributable value.
16	1/24/2021	Kim, Ye Darm	3.3	Prepare allocation analysis of scenarios.
16	1/24/2021	Kim, Ye Darm	1.8	Prepare slides re: distributable value allocation scenarios.
16	1/24/2021	Kim, Ye Darm	0.8	Process revisions to distributable value allocation slides.
16	1/24/2021	Kim, Ye Darm	1.4	Process revisions to model re: distributable value allocation analysis.
16	1/24/2021	Kim, Ye Darm	0.7	Review financial support for revised bid.
16	1/24/2021	Diaz, Matthew	1.5	Review the updated plan b analysis assumptions.
16	1/24/2021	Diaz, Matthew	1.9	Review the updated side by side analysis.
16	1/24/2021	Kim, Ye Darm	1.2	Review updated distributable value allocation model.
16	1/24/2021	Kim, Ye Darm	1.1	Review updated draft of economic analysis of strategic options presentation.
16	1/25/2021	Kim, Ye Darm	1.4	Analyze Debtors' working capital changes for min cash analysis.
16	1/25/2021	Kim, Ye Darm	1.9	Continue processing revisions to presentation re: min cash distribution requirements.
16	1/25/2021	Bromberg, Brian	0.8	Discuss minimum cash sweep payments with internal team.
16	1/25/2021	Bromberg, Brian	1.3	Finalize and distribute minimum cash requirements slides.
16	1/25/2021	Diaz, Matthew	1.5	Participate in a call with the UCC and the AHC to discuss the side by side analysis.
16	1/25/2021	Simms, Steven	0.5	Participate in call on cash flow and distributions.
16	1/25/2021	Kim, Ye Darm	1.4	Participate in call with AHC re: economic analysis of strategic options.
16	1/25/2021	Kim, Ye Darm	0.7	Participate in call with UCC re: distributable value assumptions.
16	1/25/2021	Bromberg, Brian	1.3	Participate in discussion re: minimum cash sweep payments with team.
16	1/25/2021	Kim, Ye Darm	0.5	Participate in pre-call w/ HL re: economic analysis of strategic options presentation.
16	1/25/2021	Diaz, Matthew	2.4	Prepare for the call on the side by side analysis.
16	1/25/2021	Kim, Ye Darm	2.2	Process revisions to analysis re: min cash distribution requirements.
16	1/25/2021	Kim, Ye Darm	0.9	Process revisions to distributable value model with HL updates.
16	1/25/2021	Kim, Ye Darm	1.3	Process revisions to min cash analysis.
16	1/25/2021	Kim, Ye Darm	1.1	Process revisions to presentation re: min cash requirements.
16	1/25/2021	Bromberg, Brian	1.7	Review minimum cash sweep payments analysis.
16	1/25/2021	Bromberg, Brian	1.7	Review minimum cash sweep payments presentation.
16	1/25/2021	Diaz, Matthew	1.8	Review the latest plan b analysis.
16	1/25/2021	Diaz, Matthew	2.1	Review the plan min cash distributions presentation.
16	1/25/2021	Diaz, Matthew	1.2	Review the updated cash distributions analysis.
16	1/25/2021	Kim, Ye Darm	1.2	Update allocation analysis for new tax assumptions.
16	1/25/2021	Kim, Ye Darm	1.6	Update latest distributable value model for updated FTI allocation analysis.
16	1/26/2021	Bromberg, Brian	0.9	Finalize and send minimum cash slides to Houlahan.
16	1/26/2021	Diaz, Matthew	0.7	Participate in a call with counsel to discuss minimum plan distributions pursuant to a plan.
16	1/26/2021	Diaz, Matthew	0.8	Participate in a call with PJT and HL to discuss minimum plan distributions.
16	1/26/2021	Kim, Ye Darm	1.0	Participate in call re: minimum cash analysis.
16	1/26/2021	Bromberg, Brian	0.7	Participate in call re: minimum cash with counsel.
16	1/26/2021	Kim, Ye Darm	0.7	Participate in call with Counsel re: mediation status.
16	1/26/2021	Kim, Ye Darm	1.9	Prepare updated analysis re: operating expense comparison analysis to bid.
16	1/26/2021	Kim, Ye Darm	1.5	Process revisions to allocation analysis re: updated tax assumption.
16	1/26/2021	Kim, Ye Darm	1.3	Process revisions to presentation re: minimum cash analysis.
16	1/26/2021	Diaz, Matthew	0.9	Review excel model calculating minimum plan distributions.
16	1/26/2021	Kim, Ye Darm	0.4	Review HL football field analysis.
16	1/26/2021	Diaz, Matthew	1.5	Review the revised minimum cash presentation.
16	1/26/2021	Kim, Ye Darm	0.8	Update allocation slides for latest tax assumptions.
16	1/27/2021	Simms, Steven	0.4	Correspond with counsel on presentation for Company discussion on min cash payments.
16	1/27/2021	Diaz, Matthew	0.9	Participate in a call with the Debtors' advisors to discuss plan distributions.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JANUARY 1, 2021 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
16	1/27/2021	Kim, Ye Darm	0.5	Participate in call re: bridging analysis for distributable value.
16	1/27/2021	Kim, Ye Darm	1.0	Participate in call re: mediation status.
16	1/27/2021	Kim, Ye Darm	1.0	Participate in call with Debtors re: distributable value assumptions.
16	1/27/2021	Kim, Ye Darm	0.3	Participate in post-call re: mediation workplan.
16	1/27/2021	Kim, Ye Darm	0.4	Participate on call re: bridging analysis for distributable values.
16	1/27/2021	Kim, Ye Darm	2.2	Prepare bridging analysis re: prior and updated distributable values.
16	1/27/2021	Kim, Ye Darm	1.7	Process revisions to bridging analysis re: distributable value.
16	1/27/2021	Kim, Ye Darm	0.9	Process updates to allocation slides for HL updated figures.
16	1/27/2021	Kim, Ye Darm	0.7	Review updated HL model re: distributable value scenarios.
16	1/28/2021	Kim, Ye Darm	0.4	Correspond with HL re: changes to scenario assumptions.
16	1/28/2021	Bromberg, Brian	1.5	Finalize and send minimum cash slides to Houlihan.
16	1/28/2021	Diaz, Matthew	0.5	Participate in a call to discuss possible revolver opportunities.
16	1/28/2021	Diaz, Matthew	0.6	Participate in a call with Houlihan on minimum plan distributions.
16	1/28/2021	Kim, Ye Darm	0.6	Process additional revisions to min cash analysis presentation.
16	1/28/2021	Kim, Ye Darm	1.3	Process revisions to minimum cash analysis presentation.
16	1/28/2021	Bromberg, Brian	1.4	Process revisions to minimum cash slides.
16	1/28/2021	Kim, Ye Darm	0.8	Process updates to min cash analysis presentation for internal comments.
16	1/28/2021	Kim, Ye Darm	0.8	Review bid diligence request list.
16	1/28/2021	Kim, Ye Darm	0.2	Review HL bid counterproposal slide.
16	1/28/2021	Kim, Ye Darm	1.1	Review HL scenarios model and updates to assumptions.
16	1/28/2021	Kim, Ye Darm	0.5	Review latest draft of strategic options presentation.
16	1/28/2021	Diaz, Matthew	0.9	Review of the updated presentation on the plan distributions.
16	1/28/2021	Simms, Steven	0.4	Review presentation for call with Company on min cash payments.
16	1/28/2021	Kim, Ye Darm	0.4	Review updated private settlement term sheet.
16	1/29/2021	Diaz, Matthew	0.8	Participate in a call with counsel and Houlihan to prepare for the call with the Debtors on the go forward Purdue structure.
16	1/29/2021	Diaz, Matthew	1.1	Participate in a call with the Debtors to discuss the go forward of Purdue.
16	1/29/2021	Bromberg, Brian	1.1	Participate in call for minimum cash discussion with Debtors.
16	1/29/2021	Simms, Steven	0.7	Participate in call with AHC professionals to prep for Call with Company on cash distributions.
16	1/29/2021	Simms, Steven	1.1	Participate in call with Debtor on cash distributions.
16	1/29/2021	Bromberg, Brian	0.8	Participate in pre call for minimum cash discussion with Debtors.
16	1/29/2021	Kim, Ye Darm	0.9	Process revisions to distributable value allocation slides for new assumptions.
16	1/29/2021	Kim, Ye Darm	0.7	Process updates to allocation slides for settlement assumptions.
16	1/29/2021	Kim, Ye Darm	0.7	Review latest HL model re: distributable value scenarios.
16	1/29/2021	Diaz, Matthew	1.3	Review of the go forward cash distributions of Purdue.
16	1/29/2021	Bromberg, Brian	1.8	Review reserve calculation for distributable value.
16	1/29/2021	Diaz, Matthew	1.8	Review the updated distributions analysis.
16	1/29/2021	Bromberg, Brian	1.1	Review updated distribution slides.
16	1/29/2021	Kim, Ye Darm	0.6	Update allocation slides to incorporate reserves.
16	1/29/2021	Kim, Ye Darm	1.3	Update distributable model for new settlement assumptions.
16	1/29/2021	Kim, Ye Darm	1.4	Update distributable model for reserve calculations.
16	1/30/2021	Kim, Ye Darm	1.0	Prepare additional sensitivities for Sackler settlement scenarios and update presentation.
16	1/30/2021	Kim, Ye Darm	1.8	Prepare analysis re: Sackler settlement sensitivities.
16	1/30/2021	Kim, Ye Darm	1.9	Prepare presentation re: Sackler settlement sensitivities.
16	1/30/2021	Kim, Ye Darm	0.9	Process revisions to allocation slides for HL's latest figures.
16	1/30/2021	Kim, Ye Darm	0.7	Process revisions to Sackler settlement sensitivity slides.
16	1/30/2021	Bromberg, Brian	2.9	Review updated Sackler contribution scenarios.
16	1/31/2021	Kim, Ye Darm	0.5	Process revisions to allocation slides for new assumptions.
16	1/31/2021	Kim, Ye Darm	0.8	Process revisions to the Sackler settlement sensitivities presentation.
16	1/31/2021	Kim, Ye Darm	0.6	Process updates to allocation model.
16	1/31/2021	Bromberg, Brian	1.0	Review latest version of domestic business scenarios presentation.
16 Total			253.2	
18	1/4/2021	Kim, Ye Darm	0.7	Process additional revisions to the transfers analysis presentation.
18	1/4/2021	Kim, Ye Darm	1.3	Process revisions to analysis re: insider holdings.
18	1/4/2021	Kim, Ye Darm	1.8	Process revisions to the transfers analysis presentation.
18	1/4/2021	Diaz, Matthew	0.7	Review the non cash transfers analysis.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JANUARY 1, 2021 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
18	1/5/2021	Kim, Ye Darm	0.6	Review summary of A-side trust provided by Huron.
18	1/7/2021	Diaz, Matthew	0.5	Participate in a call with Huron to discuss various A-side and B-side due diligence items.
18	1/7/2021	Kim, Ye Darm	0.5	Participate in call w/ Huron re: Family A/B asset support files.
18	1/7/2021	Bromberg, Brian	0.6	Participate in call with Huron on asset backup.
18	1/7/2021	Bromberg, Brian	0.8	Review asset backup files from Sacklers.
18	1/7/2021	Kim, Ye Darm	0.7	Review Family A/B asset support documents.
18	1/12/2021	Kim, Ye Darm	0.7	Review supporting schedule of trust assets re: Sackler assets.
18	1/13/2021	Bromberg, Brian	1.6	Review Sackler asset supporting schedule information.
18	1/14/2021	Bromberg, Brian	2.4	Assemble prior information on Sackler assets.
18	1/14/2021	Diaz, Matthew	0.6	Review certain documents to be sent to KL re: collateral issues.
18	1/15/2021	Bromberg, Brian	0.6	Participate in call with Counsel re: Sackler assets.
18	1/15/2021	Kim, Ye Darm	0.5	Participate in call with Counsel re: settlement collateral.
18	1/20/2021	Diaz, Matthew	0.9	Participate in a call with the UCC and the AHC's advisors to discuss the plan b analysis.
18	1/26/2021	Diaz, Matthew	0.5	Participate in a call with the AHC sub-mediation group to discuss mediation.
18	1/27/2021	Bromberg, Brian	1.4	Participate in meeting with Sackler counsel and meeting debrief.
18	1/27/2021	Diaz, Matthew	1.0	Participate in the mediation between the Sacklers and the AHC.
18	1/29/2021	Bromberg, Brian	0.4	Review new Sackler proposed terms.
18	1/30/2021	Diaz, Matthew	0.8	Design the sensitivity slides on the Sackler report.
18	1/30/2021	Diaz, Matthew	1.0	Participate in a call with counsel to discuss the Sackler settlement and related next steps.
18	1/30/2021	Diaz, Matthew	0.8	Participate in a call with Houlihan to discuss and design certain analyses related to the proposed Sackler settlement.
18	1/30/2021	Diaz, Matthew	0.9	Review the sensitivity slides on the Sackler settlement.
18	1/31/2021	Diaz, Matthew	1.1	Review the updated Sackler analysis presentation.
18 Total			23.4	
19	1/4/2021	Kim, Ye Darm	1.0	Participate in call re: Purdue workstream updates.
19	1/4/2021	Kurtz, Emma	0.7	Participate in internal call to discuss outstanding items and upcoming deliverables.
19	1/4/2021	Kim, Ye Darm	0.6	Participate on pre-call to prepare list of workstreams to discuss with team.
19	1/4/2021	Diaz, Matthew	0.6	Review case open items and related next steps.
19	1/4/2021	Kurtz, Emma	1.1	Review recently received diligence documents to share with team.
19	1/12/2021	Simms, Steven	0.4	Participate in correspondence with team on case items.
19	1/13/2021	Kurtz, Emma	0.6	Prepare updates to dataroom index to incorporate recently received diligence documents to share with team.
19	1/20/2021	Simms, Steven	0.6	Participate on call re: updates on ongoing case items.
19	1/25/2021	Kurtz, Emma	0.7	Review recently received dataroom files to share with team.
19	1/26/2021	Simms, Steven	0.6	Review and discuss presentation on cash payments.
19 Total			6.9	
21	1/6/2021	Diaz, Matthew	1.0	Participate in a call with the AHC meditation group to discuss future of Purdue issues.
21	1/6/2021	Diaz, Matthew	0.7	Participate in a call with the full AHC to discuss mediation, future of Purdue and other topics.
21	1/6/2021	Bromberg, Brian	0.7	Participate in Committee Call re: mediation.
21	1/6/2021	Kim, Ye Darm	1.1	Participate in weekly AHC meeting re: diligence updates.
21	1/13/2021	Kim, Ye Darm	1.0	Participate in committee call re: diligence updates.
21	1/13/2021	Suric, Emil	1.0	Participate in meeting with AHC to discuss diligence updates.
21	1/13/2021	Diaz, Matthew	1.0	Participate in the AHC call to discuss the status of the mediation, the proposed bid and other topics.
21	1/13/2021	Diaz, Matthew	0.4	Prepare for the AHC call re: mediation, bid, and other topics.
21	1/20/2021	Diaz, Matthew	1.1	Participate in a meeting with the AHC re: bid diligence.
21	1/20/2021	Kim, Ye Darm	1.0	Participate in weekly committee call re: bid diligence.
21	1/20/2021	Bromberg, Brian	0.9	Participate in weekly Committee call re: diligence updates.
21	1/27/2021	Diaz, Matthew	1.3	Participate in the AHC call to discuss the mediation and other topics.
21	1/27/2021	Diaz, Matthew	1.2	Participate in the call with the AHC to discuss mediation and other topics.
21	1/27/2021	Kim, Ye Darm	1.0	Participate in weekly committee call re: bid diligence.
21	1/27/2021	Bromberg, Brian	1.0	Participate in weekly Committee call re: updated bid diligence.
21 Total			14.4	
24	1/8/2021	Kim, Ye Darm	1.3	Prepare Purdue Dec fee statement.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JANUARY 1, 2021 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
24	1/29/2021	Kim, Ye Darm	2.4	Prepare the December fee app.
24	1/29/2021	Kim, Ye Darm	2.3	Prepare the December fee app.
24	1/29/2021	Hellmund-Mora, Maril	0.7	Update and finalize the November fee application
24 Total			6.7	
28	1/6/2021	Bromberg, Brian	0.8	Review IAC presentation for updates.
28	1/7/2021	Kurtz, Emma	0.3	Prepare updates to IAC update presentation per comments from Houlihan.
28	1/7/2021	Kim, Ye Darm	2.2	Review GL data and prepare P&L analysis.
28	1/7/2021	Kim, Ye Darm	0.4	Review HL updated slide re: IAC diligence.
28	1/7/2021	Bromberg, Brian	1.0	Review IAC general ledger file.
28	1/8/2021	Bromberg, Brian	0.8	Finalize draft IAC update and send to counsel.
28	1/8/2021	Kim, Ye Darm	0.5	Participate in call re: IAC GL Analysis.
28	1/8/2021	Kim, Ye Darm	0.9	Review GL hierarchy data provided by Huron.
28	1/8/2021	Kim, Ye Darm	1.3	Revise GL analysis for account items.
28	1/11/2021	Kim, Ye Darm	3.1	Analyze IAC general ledger information by account level.
28	1/11/2021	Kim, Ye Darm	0.6	Participate in call re: IAC general ledger information.
28	1/11/2021	Kurtz, Emma	0.4	Participate in call to discuss 2021 business plan projections backup file received from the Company.
28	1/11/2021	Kim, Ye Darm	0.9	Prepare draft question list for IAC advisors re: general ledger data.
28	1/11/2021	Kim, Ye Darm	2.7	Process revisions to the IAC general ledger analysis.
28	1/11/2021	Bromberg, Brian	1.9	Review IAC financial information.
28	1/11/2021	Bromberg, Brian	1.3	Review IAC general ledger file.
28	1/11/2021	Diaz, Matthew	1.1	Review the updated IAC business plan.
28	1/12/2021	Bromberg, Brian	0.5	Discuss IAC GL file with Houlihan.
28	1/12/2021	Diaz, Matthew	0.5	Participate in a call with Alix to discuss the updated IAC Plan.
28	1/12/2021	Kim, Ye Darm	0.5	Participate in call to discuss IAC general ledger analysis with HL.
28	1/12/2021	Kim, Ye Darm	0.8	Review HL general ledger analysis re: IAC forecasts.
28	1/12/2021	Diaz, Matthew	0.8	Review the updated IAC business plan supporting financials.
28	1/14/2021	Kurtz, Emma	1.3	Prepare summary for Counsel re: key IAC entities.
28	1/14/2021	Kurtz, Emma	0.4	Prepare updates to summary of key IAC entities for Counsel to include relevant organizational charts.
28	1/15/2021	Kurtz, Emma	0.7	Participate in call with Counsel to discuss potential collateral value of the IACs for deal with Sacklers.
28	1/22/2021	Bromberg, Brian	0.5	Review new IAC financial support files.
28	1/22/2021	Kurtz, Emma	0.3	Review recently received IAC business plan support files to summarize for team.
28	1/25/2021	Kurtz, Emma	1.6	Prepare analysis to reconcile general ledger files to 2021 business plan.
28	1/26/2021	Kurtz, Emma	2.9	Analyze intercompany general ledger entries and total general ledger entries to evaluate how they tie to 2021 P&L.
28	1/26/2021	Kurtz, Emma	2.2	Incorporate intercompany general ledger entries for 2022 through 2025 into comparison analysis to the 2021 business plan.
28	1/26/2021	Bromberg, Brian	1.3	Review provided IAC financial information.
28 Total			34.5	
29	9/30/2020	Diaz, Matthew	0.3	Review of the updated mediation order.
29	10/20/2020	Kim, Ye Darm	0.7	Review accrued bill for intercreditor allocation work.
29	11/3/2020	Kim, Ye Darm	2.6	Prepare draft of intercreditor allocation fee application.
29 Total			3.6	
Grand Total			613.0	